Global contract development and manufacturing organization (CDMO) Recipharm, said it is expanding its pMDI product development expertise to accommodate the increasing demand from pharmaceutical companies as they begin the transition to the next generation of propellants over the coming years. These new propellant gases have 90% to 99.9% lower global warming potential (GWP) than HFA134a. “We are committed to decarbonization and helping our customers meet their sustainability objectives by tran...